Axerion Therapeutics

Axerion Therapeutics is a biotech company focused on developing innovative therapeutics for neurological diseases and injuries.

Axerion Therapeutics, Inc. is a private Connecticut-based biotechnology company focused on developing innovative therapeutics for neurological diseases and injuries with significant unmet medical need, including Alzheimerâ€s disease and spinal cord injury. Axerion was established in New Haven to develop and commercialize intellectual property licensed from Dr. Stephen Strittmatterâ€s laboratory at Yale University. Axerionâ€s proprietary technology platforms include blockers of ß-amyloid (Aß) oligomers binding to Prion Proteins (PrP) on the cell surface of neurons as a novel therapeutic target for Alzheimerâ€s disease and Nogo Receptor decoy protein for recovery of neurological function in spinal cord injury and other neurological diseases.